Drugs / EG017
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05673694 | Mar 2023 → Nov 2025 | breast cancer | Changchun GeneScience Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06133166 | Sep 2023 → May 2024 | — | Changchun GeneScience Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT05674045 | Jan 2022 | female stress incontinence | Changchun GeneScience Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EG017 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05673694 ↗ |
| Route | Oral | “EG017 3mg/day Oral administration for 12 weeks, once daily” NCT05674045 ↗ |